Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Atara Biotherapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 37 | 41 | +4 |
| Shares | 1.88M | 2.05M | +166.5K (+8.8%) |
| Value | $27.0M | $37.1M | +$10.1M (+37.4%) |
New holders (7)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 18,296 | $331.0K | 0.00% |
| Citadel Advisors LLC | 15,577 | $281.8K | 0.00% |
| Susquehanna International Group, LLP | 14,018 | $253.6K | 0.00% |
| Walleye Capital LLC | 12,169 | $220.1K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 10,446 | $189.0K | 0.00% |
| Dimensional Fund Advisors LP | 10,028 | $181.4K | 0.00% |
| Federated Hermes, Inc. | 130 | $2.35K | 0.00% |
Sold out (3)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Gsa Capital Partners LLP | 26,213 | $376.0K |
| Group One Trading, L.P. | 148 | $2.12K |
| Alexis Investment Partners, LLC | 15 | $215 |